Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New cold sore cream shows promise in small study

NCT ID NCT06558838

First seen Jan 10, 2026 · Last updated Jun 22, 2026 · Updated 27 times

Summary

This study tested a cream containing acyclovir and penciclovir against an over-the-counter cream (Abreva) for preventing cold sores caused by UV light. Forty adults with a history of cold sores were exposed to UV light to trigger an outbreak, then treated with one of the creams. Researchers tracked whether the cold sore progressed to a blister and how quickly it healed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HERPES LABIALIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University of Utah MidValley Dermatology

    Murray, Utah, 84107, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

acyclovir-penciclovir cream

What this could lead to

If it works, this could point toward a more effective cream for preventing cold sores from forming after sun exposure.

What could go wrong

This is a small, early pilot study with only 40 people, so results may not apply to everyone. The cream may not work better than the existing treatment.

Conditions

The condition(s) this trial relates to.

herpes labialis herpes simplex virus gingivostomatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.